Price
$1.78
Increased by +5.33%
Dollar volume (20D)
286.11 K
ADR%
15.13
Shares float
15.60 M
Shares short
191.93 K [1.23%]
Shares outstanding
39.12 M
Market cap
66.12 M
Beta
0.76
Price/earnings
N/A
20D range
1.38 5.59
50D range
1.38 17.17
200D range
1.38 17.17

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.

The company is based in Irvine, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 13, 23 1.15
Increased by +2.32 K%
-0.53
Increased by +316.98%
Aug 30, 23 -0.44
Decreased by -918.48%
-
May 31, 23 -0.02
Decreased by -124.13%
-
Dec 31, 22 0.00
Decreased by -62.50%
-
Sep 30, 22 0.05
Increased by +106.52%
-
Jun 30, 22 0.05
Increased by +146.36%
-
Mar 31, 22 0.08 -
Dec 31, 21 0.01 -
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 N/A
Decreased by N/A%
N/A
Decreased by N/A%
- -
Mar 31, 23 N/A - N/A - - -
Dec 31, 22 0.00 - -34.56 M -
Decreased by N/A%
-
Sep 30, 22 0.00 - -10.44 M -
Decreased by N/A%
-
Jun 30, 22 N/A - N/A - - -
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY